Oruka Therapeutics, Inc. (ORKA) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Is Oruka Therapeutics, Inc. stock overvalued or undervalued in 2026?
As of November 3, 2026, Oruka Therapeutics, Inc. (ORKA) trades at $99.55 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Oruka Therapeutics, Inc.
Market cap $7B · 52 weeks $26 – $113 (12 % below the high) · P/E no earnings · Dividend none · Next earnings November 11, 2026 · expected EPS -$0.60 · Closing price, Nov 3 · accounts published Aug 10.
- Valuation: P/E — (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 6 of 8 (no verdict).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 0.0 %, fails.
- Market cap / Cash 13.5×, fails.
- Cash Runway 46 months, passes.
- Total Debt 0.0×, passes.
- Annual cash burn $1.93, info.
Against its peers (reference peers) — Oruka Therapeutics, Inc.: P/E —; EV/EBITDA —; ROIC -13.9 %; $6.6B. Ligand Pharmaceuticals Incorporated (P/E 140×; EV/EBITDA 93.2×; ROIC 2.3 %; $6.3B), PTC Therapeutics, Inc. (P/E —; EV/EBITDA 29.9×; ROIC 5.7 %; $5.7B), Krystal Biotech, Inc. (P/E 41.4×; EV/EBITDA 34.0×; ROIC 13.7 %; $9.0B).
Profitability
| Return on Equity | -20.76% |
| Return on Invested Capital | -13.88% |
| Return on Assets | -11.66% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 38.51 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 49.15 |
Price Performance
| 1 month | +17.98% |
| 3 months | +1.15% |
| Year-to-date | +228.44% |
| 1 year | +262.92% |
| 3 years | +336.62% |
| 5 years | +215.43% |
| 10 years | -79.52% |
Dividend History
| Date | Amount |
|---|---|
| August 29, 2024 | $19.356 |
Amounts adjusted for stock splits.
Related companies: DNTH · XNCR · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ORKA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks